Table 2.

Experimental therapies.

1. Management of cholestasis

I. Additional anti-cholestatic drugs:

LJN-452 [ClinicalTrials.gov identifier: NCT02516605]

NGM-282 [ClinicalTrials.gov identifiers: NCT02026401 and NCT02135536]

MBX-8025 [ClinicalTrials.gov identifier: NCT02609048]

GS-9674 (Gilead) [ClinicalTrials.gov identifier: NCT02943447]

Elafibranor [ClinicalTrials.gov identifier: NCT03124108]

II. Immunotherapy agent:

FFP-104 [ClinicalTrials.gov identifier: NCT02193360]

III. Experimental therapies:

Phototherapy

Plasmapheresis

Nasobiliary drainage

Albumin dialysis (Molecular Adsorbent Recirculating System)

2. Management of symptoms

I. Pruritus:

Molecules in trials:

GSK2330672 [ClinicalTrials.gov identifier: NCT01899703]

Lopixibat [ClinicalTrials.gov identifier: NCT01904058]

II. Fatigue:

Rituximab (RITPBC trial) [ClinicalTrials.gov identifier: NCT02376335]